Home DNA Damage/DNA Repair CRISPR/Cas9

CRISPR/Cas9

CRISPR/Cas9 Products

  • All (10)
  • CRISPR/Cas9 Inhibitors (2)
  • CRISPR/Cas9 Activators (7)
  • CRISPR/Cas9 Modulator (1)
  • New CRISPR/Cas9 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2638 NU7441 (KU-57788) NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.
Nat Cell Biol, 2024, 10.1038/s41556-024-01394-y
Nat Commun, 2024, 15(1):6517
Nat Commun, 2024, 15(1):7076
S2775 Nocodazole Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole induces apoptosis.
Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0
Nat Commun, 2024, 15(1):9771
Nucleic Acids Res, 2024, gkae605
S7046 Brefeldin A (BFA) Brefeldin A (BFA) is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Nat Commun, 2024, 15(1):203
Cancer Commun (Lond), 2024, 10.1002/cac2.12583
Cell Rep Med, 2024, S2666-3791(24)00544-5
S7742 SCR7 SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
MedComm (2020), 2024, 5(8):e690
iScience, 2024, 27(2):108814
Nat Commun, 2023, 14(1):4761
S7827 4-Hydroxytamoxifen (Afimoxifene) 4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.
Nat Commun, 2024, 15(1):8641
Nat Commun, 2024, 15(1):2983
Cell Rep Med, 2024, 5(3):101468
S2579 Zidovudine Zidovudine (ZDV, Azidothymidine, NSC 602670) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV. It could decrease the HDR efficiency and decrease CRISPR-mediated sequence-specific genome knockin events while increaseing knockout efficiency.
Nat Commun, 2024, 15(1):2716
Nat Commun, 2024, 15(1):9321
J Immunother Cancer, 2024, 12(11)e009805
S7974 L755507 L-755,507 is characterized as a potent and selective β3 adrenergic receptor partial agonist with EC50 of 0.43 nM. It is also recently identified to enhance CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs) and other cell types.
Front Cell Dev Biol, 2023, 11:1276890
bioRxiv, 2023, 10.1101/2023.10.03.560773
Genesis, 2022, 60(1-2):e23465
S8234 RS-1 RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.
J Biomed Sci, 2024, 31(1):68
Int J Biol Sci, 2021, 17(4):1026-1040
Chembiochem, 2021, 22(20):2957-2965
S8844 BRD0539 BRD0539 is a potent inhibitor of Streptococcus pyogenes Cas9 (SpCas9) with IC50 of 22 μM in an in vitro DNA cleavage assay.
Mol Cell, 2021, S1097-2765(21)00168-4
S0102 L 189 L 189 is a novel human DNA ligase inhibitor with IC50 of 5 μM, 9 μM and 5 μM for hLigI, hLigIII and hLigIV, respectively. L 189 inhibits base excision repair (BER) and non-homologous end joining (NHEJ). L 189 specifically sensitizes cancer cells to DNA damage.
S8844 BRD0539 BRD0539 is a potent inhibitor of Streptococcus pyogenes Cas9 (SpCas9) with IC50 of 22 μM in an in vitro DNA cleavage assay.
Mol Cell, 2021, S1097-2765(21)00168-4
S0102 L 189 L 189 is a novel human DNA ligase inhibitor with IC50 of 5 μM, 9 μM and 5 μM for hLigI, hLigIII and hLigIV, respectively. L 189 inhibits base excision repair (BER) and non-homologous end joining (NHEJ). L 189 specifically sensitizes cancer cells to DNA damage.
S2638 NU7441 (KU-57788) NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM and also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively. It reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.
Nat Cell Biol, 2024, 10.1038/s41556-024-01394-y
Nat Commun, 2024, 15(1):6517
Nat Commun, 2024, 15(1):7076
S2775 Nocodazole Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole induces apoptosis.
Nat Cell Biol, 2024, 10.1038/s41556-024-01473-0
Nat Commun, 2024, 15(1):9771
Nucleic Acids Res, 2024, gkae605
S7046 Brefeldin A (BFA) Brefeldin A (BFA) is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
Nat Commun, 2024, 15(1):203
Cancer Commun (Lond), 2024, 10.1002/cac2.12583
Cell Rep Med, 2024, S2666-3791(24)00544-5
S7742 SCR7 SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
MedComm (2020), 2024, 5(8):e690
iScience, 2024, 27(2):108814
Nat Commun, 2023, 14(1):4761
S7827 4-Hydroxytamoxifen (Afimoxifene) 4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.
Nat Commun, 2024, 15(1):8641
Nat Commun, 2024, 15(1):2983
Cell Rep Med, 2024, 5(3):101468
S7974 L755507 L-755,507 is characterized as a potent and selective β3 adrenergic receptor partial agonist with EC50 of 0.43 nM. It is also recently identified to enhance CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs) and other cell types.
Front Cell Dev Biol, 2023, 11:1276890
bioRxiv, 2023, 10.1101/2023.10.03.560773
Genesis, 2022, 60(1-2):e23465
S8234 RS-1 RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.
J Biomed Sci, 2024, 31(1):68
Int J Biol Sci, 2021, 17(4):1026-1040
Chembiochem, 2021, 22(20):2957-2965
S2579 Zidovudine Zidovudine (ZDV, Azidothymidine, NSC 602670) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV. It could decrease the HDR efficiency and decrease CRISPR-mediated sequence-specific genome knockin events while increaseing knockout efficiency.
Nat Commun, 2024, 15(1):2716
Nat Commun, 2024, 15(1):9321
J Immunother Cancer, 2024, 12(11)e009805

Choose Selective CRISPR/Cas9 Inhibitors

Tags: CRISPR/Cas9 enhancer|CRISPR/Cas9 activator|CRISPR/Cas9 inhibitor